Clinical Trial Update: Study of ACE-536 in Healthy Postmenopausal Women [Phase 1]

View source ↗

Summary

Phase 1 study of ACE-536 in healthy postmenopausal women has completed, evaluating safety in the context of anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• ACE-536

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Anemia | Phase 1 | Status: COMPLETED